STEADYMED LTD. (STDY) financial statements (2021 and earlier)

Company profile

Business Address 5 OPPENHEIMER STREET
REHOVOT, 76701
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments21273237441523
Cash and cash equivalents21273237441523
Restricted cash and investments  0   0
Other undisclosed current assets0101000
Total current assets:21273338441523
Noncurrent Assets
Property, plant and equipment6656555
Deposits noncurrent assets0000000
Assets held-in-trust0000000
Total noncurrent assets:6666555
TOTAL ASSETS:28333844492028
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3212223
Accounts payable21 221 
Accrued liabilities  1   2
Employee-related liabilities  1   1
Other undisclosed accounts payable and accrued liabilities11 (0)(0)1 
Deferred revenue and credits 0011
Other undisclosed current liabilities2112213
Total current liabilities:4334446
Noncurrent Liabilities
Liabilities, other than long-term debt1111000
Accounts payable and accrued liabilities0000000
Liability, pension and other postretirement and postemployment benefits0000000
Other undisclosed noncurrent liabilities1816111024207
Total noncurrent liabilities:1916121125207
Total liabilities:24191514292414
Stockholders' equity
Stockholders' equity attributable to parent414242920(4)14
Common stock0000000
Additional paid in capital137136136136136104103
Accumulated deficit(133)(123)(112)(106)(116)(108)(89)
Total stockholders' equity:414242920(4)14
TOTAL LIABILITIES AND EQUITY:28333844492028

Income statement (P&L) ($ in millions)

6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
Gross profit:  00000
Operating expenses(7)(6)(5)(5)(5)(6)(7)
Operating loss:(7)(6)(5)(5)(5)(6)(6)
Nonoperating income (expense)(3)(4)(1)14(3)(13)4
Interest and debt expense (4)(1)  (13) 
Other undisclosed loss from continuing operations before equity method investments, income taxes      (1)
Income (loss) from continuing operations before equity method investments, income taxes:(10)(14)(7)9(8)(31)(3)
Other undisclosed income from continuing operations before income taxes 41  131
Income (loss) from continuing operations before income taxes:(10)(10)(6)9(8)(18)(2)
Income tax expense (benefit)(0)(0)(0)0(0)(0)(0)
Net income (loss) available to common stockholders, diluted:(10)(10)(6)9(8)(19)(2)

Comprehensive Income ($ in millions)

6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
Net income (loss):(10)(10)(6)9(8)(19)(2)
Comprehensive income (loss), net of tax, attributable to parent:(10)(10)(6)9(8)(19)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: